Verici Dx signs licensing deal with Thermo Fisher for kidney rejection test
Verici Dx plc, a pioneer in clinical diagnostics for organ transplant, has announced an exclusive global licensing agreement with Thermo Fisher Scientific, a world leader in science services, to develop a diagnostic assay for early kidney rejection risk assessment.
Exclusive Licensing Terms
The agreement provides Thermo Fisher with exclusive rights to develop and market the assay globally, including the option to manufacture, distribute, and sell. The partnership involves an upfront payment to Verici Dx, with additional payments contingent on various operational milestones related to technology transfer and publications.
Non-Exclusive Access to Research Data
Verici Dx has also granted Thermo Fisher non-exclusive access to a portion of its urine sample data, showcasing the value in the Company’s research assets. The financial arrangements include an expected total payment to Verici Dx of approximately $5 million over the next 12 months, followed by additional compensation and ongoing royalties on future test sales.
Thermo Fisher to develop advanced kidney transplant rejection assay under Verici Dx license
Leadership Comments on the Collaboration
Sara Barrington, CEO of Verici Dx, expressed pride in their advancements and the potential impact of collaborating with Thermo Fisher: “We are incredibly proud of our advancements in transforming potential outcomes for kidney transplant patients. By collaborating with Thermo Fisher, we believe we can accelerate the development of our technology, helping ensure that it reaches those who need it the most.”
Nicole Brockway, President of Transplant Diagnostics at Thermo Fisher Scientific, commented on the need for effective transplant rejection tests: “There is a significant need for effective tests that can identify the risk of transplant rejection early to help inform treatment decisions. Our hope is that this licensing agreement will allow us to develop a new prognostic assay that will expand and strengthen our portfolio of transplant testing solutions.”
This agreement between Verici Dx and Thermo Fisher Scientific marks a significant advancement in the field of transplant diagnostics, with potential benefits for kidney transplant patients worldwide.